Macitentan denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Macitentan as Duplicate Therapy — And Why You Can Appeal

Macitentan is an endothelin receptor antagonist (ERA) indicated for pulmonary arterial hypertension (PAH). A duplicate-therapy denial means Aetna determined that you are already receiving a medication it considers therapeutically equivalent or overlapping — most commonly another ERA. However, the clinical management of PAH often involves intentional combination therapy with agents from the same or different classes, based on the patient's WHO functional class, risk stratification, and treatment response. A duplicate-therapy denial in this context frequently reflects a plan policy that does not align with current PAH treatment guidelines.

## Why This Denial Is Appealable

The duplicate-therapy classification assumes the two agents are interchangeable, but your prescribing physician's clinical judgment — documented in the chart — is that macitentan serves a distinct or additive role in your treatment plan. PAH specialty guidelines from the applicable professional society (such as those from the relevant cardiovascular or pulmonary hypertension guideline organization) address combination therapy strategies. Your appeal should document why macitentan is not duplicative but rather a specifically chosen component of your PAH management regimen.

## Federal Appeal Framework

• Internal appeal: File within the timeframe stated in your denial letter. Standard review is typically 60 days; expedited review (72 hours) is available if your condition is urgent.
• External review (ACA §2719): After exhausting the internal appeal, an independent IRO external review is available, generally within four months of the final internal denial.
• ERISA §503: Employer-sponsored plans must conduct a full-and-fair review of all clinical evidence submitted.

## Documentation to Gather

• Current medication list and PAH treatment history: documenting all prior and current PAH therapies, with dates, dose adjustments, and clinical response
• Functional status and risk assessments: chart records of WHO functional class, six-minute walk test results, and other objective measures of disease severity and trajectory
• Prescriber medical-necessity letter: from your PAH specialist, specifically explaining why macitentan is not duplicative — addressing what clinical goal it serves that is distinct from or additive to the existing regimen
• PAH specialist notes: supporting the combination therapy approach
• Aetna's coverage policy: identify the duplicate-therapy language in Aetna's clinical policy bulletin for PAH medications and address each criterion
• Applicable guideline organization reference: a general citation to the relevant PAH guideline body supporting the treatment strategy (without citing specific numbers or statistics)

## Criteria-Mapping Structure

Your appeal letter should directly refute the duplicate-therapy characterization by explaining the pharmacological or clinical distinction between the agents. For each element of Aetna's duplicate-therapy criterion, provide a chart-backed response. Attach all referenced records as labeled exhibits.